An Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

Trial Profile

An Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs Brexanolone (Primary)
  • Indications Status epilepticus
  • Focus Adverse reactions
  • Sponsors Sage Therapeutics
  • Most Recent Events

    • 05 Aug 2017 Results published in the Annals of Neurology
    • 28 Apr 2017 Results assessing the hemodynamic properties of SAGE-547 injection, presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results of pharmacokinetic assessment of standard and high dosing of SAGE-547 injection, presented at the 69th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top